Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (27.04.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 27.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp |
| 12.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 01.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 15.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 01.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 12.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 21.10.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 15.09.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai |
| 13.12.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certai |
| 10.12.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 01.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 19.02.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offi |
| 20.11.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 27.02.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 11.02.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Unternehmen & Branche
| Name | ABBOTT LABORATORIES |
|---|---|
| Ticker | ABT |
| CIK | 0000001800 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 028241000 |
|---|---|
| ISIN | US0282410002 |
| Typ | Common Stock |
| Marktkapitalisierung | 159,66 Mrd. USD |
| Beta | 0,78 |
| Dividendenrendite | 2,44 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 44,328,000,000 | 6,524,000,000 | 3.72 | 86,713,000,000 | 52,130,000,000 |
| 2025-09-30 | 10-Q | 11,369,000,000 | 1,644,000,000 | 0.94 | 84,181,000,000 | 50,954,000,000 |
| 2025-06-30 | 10-Q | 11,142,000,000 | 1,779,000,000 | 1.01 | 83,999,000,000 | 50,565,000,000 |
| 2025-03-31 | 10-Q | 10,358,000,000 | 1,325,000,000 | 0.76 | 81,448,000,000 | 48,811,000,000 |
| 2024-12-31 | 10-K | 41,950,000,000 | 13,402,000,000 | 7.64 | 81,414,000,000 | 47,664,000,000 |
| 2024-09-30 | 10-Q | 10,635,000,000 | 1,646,000,000 | 0.94 | 74,356,000,000 | 39,796,000,000 |
| 2024-06-30 | 10-Q | 10,377,000,000 | 1,302,000,000 | 0.74 | 73,017,000,000 | 39,318,000,000 |
| 2024-03-31 | 10-Q | 9,964,000,000 | 1,225,000,000 | 0.70 | 72,467,000,000 | 38,810,000,000 |
| 2023-12-31 | 10-K | 40,109,000,000 | 5,723,000,000 | 3.26 | 73,214,000,000 | 38,603,000,000 |
| 2023-09-30 | 10-Q | 10,143,000,000 | 1,436,000,000 | 0.82 | 72,090,000,000 | 37,481,000,000 |
| 2023-06-30 | 10-Q | 9,978,000,000 | 1,375,000,000 | 0.78 | 73,354,000,000 | 37,174,000,000 |
| 2023-03-31 | 10-Q | 9,747,000,000 | 1,318,000,000 | 0.75 | 73,794,000,000 | 37,010,000,000 |
| 2022-12-31 | 10-K | 43,653,000,000 | 6,933,000,000 | 3.91 | 74,438,000,000 | 36,686,000,000 |
| 2022-09-30 | 10-Q | 10,410,000,000 | 1,435,000,000 | 0.81 | 72,801,000,000 | 35,675,000,000 |
| 2022-06-30 | 10-Q | 11,257,000,000 | 2,018,000,000 | 1.14 | 74,202,000,000 | 36,490,000,000 |
| 2022-03-31 | 10-Q | 11,895,000,000 | 2,447,000,000 | 1.37 | 74,007,000,000 | 35,399,000,000 |
| 2021-12-31 | 10-K | 43,075,000,000 | 7,071,000,000 | 3.94 | 75,196,000,000 | 35,802,000,000 |
| 2021-09-30 | 10-Q | 10,928,000,000 | 2,100,000,000 | 1.17 | 73,795,000,000 | 34,422,000,000 |
| 2021-06-30 | 10-Q | 10,223,000,000 | 1,189,000,000 | 0.66 | 73,269,000,000 | 33,800,000,000 |
| 2021-03-31 | 10-Q | 10,456,000,000 | 1,793,000,000 | 1.00 | 72,785,000,000 | 33,562,000,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Ironwood Investment Counsel, LLC | 12,295 | 0 | 12,295 | 1,540,552 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | STARKS DANIEL J | Director | Open Market Purchase | 10,000 | 92.65 | 926,537.00 | +216,1% | |
| 2026-04-23 | Boudreau Philip P | Officer, EVP AND CFO | Open Market Purchase | 2,200 | 91.50 | 201,300.00 | +47,0% | |
| 2026-03-02 | Salvadori Daniel Gesua Sive | Officer, EVP AND GROUP PRESIDENT | Open Market Sale | -885 | 115.58 | -102,288.30 | -23,9% | |
| 2026-03-02 | Cushman Elizabeth C. | Officer, EVP, GC AND SECRETARY | Open Market Sale | -263 | 115.58 | -30,397.54 | -7,1% | |
| 2026-03-02 | MCCOY JOHN A. JR. | Officer, VICE PRESIDENT AND CONTROLLER | Open Market Sale | -585 | 115.58 | -67,614.30 | -15,8% | |
| 2026-03-02 | Moreland Mary K | Officer, EXECUTIVE VICE PRESIDENT | Open Market Sale | -613 | 115.58 | -70,850.54 | -16,5% | |
| 2026-03-02 | Shroff Eric | Officer, Senior Vice President | Open Market Sale | -709 | 115.58 | -81,946.22 | -19,1% | |
| 2026-03-02 | Morrone Louis H. | Officer, EXECUTIVE VICE PRESIDENT | Open Market Sale | -1,144 | 115.58 | -132,223.52 | -30,8% | |
| 2026-02-04 | STARKS DANIEL J | Director | Open Market Purchase | 4,967 | 109.14 | 542,092.42 | +126,5% | |
| 2026-02-04 | STARKS DANIEL J | Director | Open Market Purchase | 5,033 | 108.33 | 545,238.98 | +127,2% | |
| 2026-01-23 | Ford Robert B | Director, Officer, CHAIRMAN AND CEO | Open Market Purchase | 18,800 | 107.13 | 2,013,966.92 | +469,8% | |
| 2025-11-25 | Shroff Eric | Officer, Senior Vice President | Open Market Sale | -1,586 | 128.02 | -203,042.57 | -47,4% | |
| 2025-08-08 | Boudreau Philip P | Officer, EVP AND CFO | Open Market Sale | -5,550 | 134.55 | -746,758.05 | -174,2% | |
| 2025-04-30 | Blount Sally E. | Director | Open Market Sale | -2,600 | 129.66 | -337,116.00 | -78,6% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Ironwood Investment Counsel, LLC | 12,295 | 1,540,552 | 100.00 |